IE55578B1 - Hollow fibre useful in blood treating processes - Google Patents
Hollow fibre useful in blood treating processesInfo
- Publication number
- IE55578B1 IE55578B1 IE1535/83A IE153583A IE55578B1 IE 55578 B1 IE55578 B1 IE 55578B1 IE 1535/83 A IE1535/83 A IE 1535/83A IE 153583 A IE153583 A IE 153583A IE 55578 B1 IE55578 B1 IE 55578B1
- Authority
- IE
- Ireland
- Prior art keywords
- hollow fibre
- hollow
- fibre
- copolymer
- fibres
- Prior art date
Links
- 239000000835 fiber Substances 0.000 title claims description 59
- 238000000034 method Methods 0.000 title claims description 24
- 239000008280 blood Substances 0.000 title description 11
- 210000004369 blood Anatomy 0.000 title description 11
- 239000002904 solvent Substances 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 31
- 229920001577 copolymer Polymers 0.000 claims description 23
- 238000005406 washing Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000499 gel Substances 0.000 claims description 18
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 6
- 235000019592 roughness Nutrition 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims description 5
- 239000003495 polar organic solvent Substances 0.000 claims description 4
- 239000012298 atmosphere Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000012456 homogeneous solution Substances 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 230000002427 irreversible effect Effects 0.000 claims description 3
- 238000009987 spinning Methods 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000011800 void material Substances 0.000 claims description 2
- 238000002616 plasmapheresis Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 238000000108 ultra-filtration Methods 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000006641 stabilisation Effects 0.000 description 6
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 238000001631 haemodialysis Methods 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 230000035699 permeability Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- -1 alkali metal salts Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002615 hemofiltration Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/40—Polymers of unsaturated acids or derivatives thereof, e.g. salts, amides, imides, nitriles, anhydrides, esters
- B01D71/42—Polymers of nitriles, e.g. polyacrylonitrile
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Artificial Filaments (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Spinning Methods And Devices For Manufacturing Artificial Fibers (AREA)
- External Artificial Organs (AREA)
Description
3 3 5 5 5 7 8 The present invention relates to semi-permeable hollow fibres useful in processes for treating blood, and in particular in artificial kidneys, and in haemodialysis and ultra-filtration apparatus.
Hollow fibres of this type have been described, for example in U.S. Patent No. 4,056,467. They have excellent mechanical properties together with valuable permeability characteristics for the dialysis and ultrafiltration of blood. They are obtained by a coagulation 10 process involving precipitation of a copolymer from solution with simultaneous extraction of the solvent. However, when these fibres are used, it is necessary to use relatively large amounts of heparin to prevent blood clots from depositing on the internal walls of the hollow 15 fibres.
Hollow fibres which can be used in haemodialysis and haemofiltration have also been obtained from polymers such as polymethyl methacrylate by processes optionally involving thermally reversible gelling, generally 20 accompanied by coagulation. Such processes lead to hollow fibres vfcose internal surface is generally not very smooth on a microscopic scale, which can lead to loss in performance characteristics during in vivo operation or can require the use of large amounts of heparin. 3 The present invention provides hollow fibres which avoid some or all of the disadvantages of the prior art fibres. More particularly, the hollow fibres of the invention have improved haemocompatibility, 5 that is to say that they, by their nature and microstructure, do not encourage the attachment of blood clots when they come into contact therewith. Such clots are capable of obstructing, or even completely blocking, the internal channels of other hollow fibres. Thus, when 10 the new fibres are used in apparatus for the treatment of blood, a very uniform circulation of the blood is possible, especially during haemofiltration, when the haematocrit can reach high values locally. The risk of embolism and the required dose of heparin are both 15 reduced, which represents both increased safety for the patient and a saving in cost.
The new hollow fibres may have improved mechanical properties and permeability to constituents of different molecular weights, which can range up to 20 60,000 daltons and even more if necessary. They also have improved efficiency and reliability.
The process for the manufacture of the new hollow fibres is simple, and has good productivity and reliability.
The semi-permeable hollow fibres of the present invention, which are useful in processes for treating blood, more particularly by haemodialysis and/or by 4 ultrafiltration, and have substantially improved haemocompatibility characteristics, are of the symmetrical type and consist of a copolymer of acrylonitrile and an olefinlcally unsaturated comonomer carrying sulphonic acid 5 groups which are optionally salified, and have a homogeneous mictoporous structure of a gel obtained essentially by lowering the temperature of a solution of the said copolymer by means of air or of an inert fluid which is immiscible with the constituents of the said 10 solution during gelling, followed by washing.
The hollow fibres of the invention are obtained by: (a) preparing a composition from a copolymer of acrylonitrile and an olefinically unsaturated comonomer 15 carrying sulphonic acid groups which may be salified, a polar organic solvent, and an adjuvant, which is a poor solvent or is not a solvent for the copolymer, is miscible with the solvent or mixture of solvents and preferably also with water and which does not contain any component capable 20 of reacting with the components of the said composition which would result in the formation of an irreversible gel before washing, (b) bringing the composition into the state of a homogeneous solution which can be spun at a temperature 25 above its gel temperature, (c) spinning the said solution through a spinneret, to form a hollow fibre and cooling the hollow fibre thus formed until it gels, and (d) washing the gelled hollow fibres to remove the non-polymeric residues therefrom.
The composition used in this process essentially 5 contains: δ (i) a copolymer of acrylonitrile and an olefinically unsaturated comonomer carrying optionally salified sulphonic acid groups, (ii) a polar organic solvent for the copolymer, and 5 (iii) an adjuvant which is a poor solvent or non-solvent for the copolymer and which is miscible with the solvent and preferably miscible with water.
The sulphonic comonomer for the acrylonitrile copolymer may be a compound of the formula: 10 CHR^ = CR3 - A - Y (1) in which Y represents -SO^H or -SO^M, M being a metal atom, preferably of an alkali metal, R^ and each represent hydrogen or methyl; and A represents a valence bond, or a group A' or -0-A1-, in which A' represents a 15 saturated or unsaturated, linear or branched divalent aliphatic hydrocarbon group, an unsubstituted aromatic nucleus, or a monoaromatic-monoaliphatic chain in which one of the free valencies is carried by an aliphatic carbon atom and the other by a carbon atom of the aromatic 20 nucleus.
Sulphonic monomers for the acrylonitrile which may be mentioned more specifically are vinylsulphonic, allylsulphonic, methallylsulphonic, styrenesulphonic, vinyloxybenzenesulphonic, allyloxybenzenesulphonic, 25 methallyloxybenzenesulphonic, allyloxyethylsulphonic and methallyloxyethylsulphonic acids and also the salts of these acids, preferably their alkali metal salts. 7 The proportion of sulphonic comonomer in the acrylonitrile copolymer is generally between 1. and 50% (by number) of sulphonic monomer units, and preferably between 3 and 15%. The acrylonitrile copolymers usually 0 5 have a specific viscosity (measured at 25 C in a dimethyl-formamide solution containing 2 g/litre) of from 0.1 to 3, preferably 0.5 to 1.5.
The solvent used in the composition to be spun is a polar organic solvent or a mixture of polar organic 10 solvents which is capable of forming a spinnable solution with the copolymer of acrylonitrile and sulphonic comonomer. Known solvents for copolymers of acrylonitrile and sulphonic comonomer, which are preferably miscible with water, are generally used as the polar organic 15 solvents. More specifically, there may be mentioned dimethyl sulphoxide, Ν,Ν-dimethylacetamide, N-methyl-pyrrolid-2-one, y-butyrolactone and especially N,N-dimethylformamide (DMF). The solution can be obtained from a mixture of solvents instead of from a single 20 solvent.
One or more components which are poor solvents or non-solvents for the copolymer and which are miscible with the solvent or mixture of solvents, and preferably miscible with water, are used as adjuvants. The adjuvant 25 facilitates the formation of a thermally reversible gel which is obtained by lowering the temperature of a 8 solution having the composition defined above. It does not contain any component capable of reacting with components of the composition which would lead to the formation of an irreversible gel.
Examples of adjuvants which can be used are ethylene glycol, hexanediol, diethylene glycol and its monoethers such as 2-ethoxyethanol and 2-butoxyethanol, and urea. However, it is preferred to use water and/or especially glycerol because they are non-toxic and 10 convenient to use.
Advantageously, the concentration of glycerol in the composition is adjusted to a level sufficient for the gelling temperature of the composition to be slightly o above 100 C which enables the solutions spun into a 15 gelled hollow fibre to be cooled simply in air at ambient temperature.
In practice, the adjuvants are employed in the composition in amounts such that the concentration by weight of copolymer is generally more than 5% and less 20 than 50%. It is preferably between 20% and 40% by weight. The ratio of solvent to adjuvant is generally from 100/1 to 0.1/1 by weight and is preferably from 10/1 to 1/1.
The temperature of the composition defined in this way is brought to values above the gelling temperature, . O 0 25 which is generally from 50 C to 150 C and preferably from 90°C to 130°C. 9 The various constituents listed above are mixed and the mixture is heated to give a spinnable homogeneous solution. The process can be carried out, in a manner which is in itself known, in any suitable 5 apparatus equipped with heating and stirring means, such as a dissolver or, preferably, an extruder.
The solution prepared in this way can be spun in the form of hollow fibres by various processes which are in themselves known. The spinneret is generally of 10 annular shape. It is preferably arranged along a vertical axis. It also possesses an axial orifice allowing air or inert gas, which is advantageously filtered, to be introduced through the spinneret, thus contributing to the support and uniform shaping of the 15 axial channel of the hollow fibre during formation.
The air or the gas can be introduced at ambient temperature and at a pressure of the order of atmospheric pressure or, advantageously, at a slight overpressure, for example at a relative pressure of less than 500 mm 20 of water.
The semi-permeable hollow fibres of the present invention are essentially obtained by spinning the solution described above at constant rate, most frequently with the aid of an injection pump operating under pressure, 25 and then cooling the spun solution below its gelling point. 16 The solution is thus converted from the liquid state to th.e gel state, that is to say to a non-fluid state still impregnated with solvent. In fact, all the components of the initial solution ate retained in the gel.
Slight losses of solvent or non-solvent by evaporation may possibly be observed, but these losses are generally not d isadvantageous.
The essential factor in the conversion of this solution is the lowering of its temperature, which results 10 in a gradual increase in its viscosity and also in the appearance of elastic properties, and which leads to a non-fluid uniform mass capable of retaining its shape under its own weight. This conversion could be reversed, if necessary, provided the elimination of the solvent has not 15 been effected by washing.
The cooling can preferably be obtained simply by contact with the atmosphere, or by the forced circulation of air, cooled beforehand if appropriate, or by the action of any other fluid - liquid or gaseous - which is inert and 20 immiscible with the constituents of the solution during gelling .
In a preferred embodiment, the solution flows vertically from the spinneret during the gelling process. It is not until the hollow fibre has reached a sufficient 25 state of solidification, enabling it to be subjected to mechanical stress while retaining its shape, that it is generally taken over by a mechanical system comprising, 11 in particular, one or more drive rollers. In practice, the distance, and preferably the height, between the spinneret and the first mechanical element coming into contact with the hollow fibre after gelling is generally 5 between 1 cm and 10 metres and preferably between 50 cm and 3 metres.
Advantageously, the hollow fibre is wound around a first drive roller, which is caused to rotate at a constant speed such that it exerts a so-called primary 10 longitudinal stretching on the hollow fibre as soon as it leaves the spinneret, when the composition is still in the fluid state.
It is observed that this primary stretching results in a simultaneous reduction in the internal and 15 especially external diameters of the hollow fibre, and hence in a substantial reduction in its thickness. It is thus possible to obtain fine hollow fibres using spinnerets having one or more relatively wide, annular orifices, which simplifies their construction and improves the 20 uniformity of their operation. Moreover, the production rate of the hollow fibre can be increased considerably.
The primary stretching ratio is in fact generally from 1/1 to 20/1 and preferably from 2/1 to 10/1.
This reduction in the thickness of the wall of 25 the hollow fibre assists rapid cooling of the composition. This conversion leads to a homogeneous microporous 12 structure without a skin, the pores still being impregnated with the solvent and adjuvant components.
They are then removed by washing.
The microporous structure obtained according 5 to the present invention is formed, in the gel state, of a mass which has on the whole retained all the constituents of the initial solution, in contrast to the processes involving either evaporation of the solvent or extraction of the solvent from a polymer solution by a coagulating 10 agent (a non-solvent for the polymer, miscible with the solvent). The use of a coagulant is therefore advantageously avoided in the present invention.
The non-polymeric residues, in particular the solvent and the adjuvant, are removed by washing the hollow 15 fibre while it is in the gel state, that is to say nonfluid, by immersing it in a washing bath. It will be noted that this bath could only have a coagulating effect insofar as the hollow fibre was still in the fluid state and not yet converted to gel.
This washing can be carried out in one or more steps including a second treatment by so-called "secondary" stretching. The washing bath used can be an aqueous mixture of organic solvents, in particular of alcohols such as methanol, but it is preferred to use pure water.
Generally, the temperature of the washing bath or baths is from 0° to 100°C and preferably from 10° to 50°C. The 13 residence time of the hollow fibre in the washing bath or baths is generally from 5 seconds to 5 minutes and preferably from 30 seconds to 2 minutes.
The washing treatment before secondary stretching 5 generally has the effect of increasing the rigidity of the hollow fibre and of reducing its permeability somewhat, which shows that there is no substantial coagulation process.
Advantageously, the porosity of the hollow 10 fibres is increased and their permeability is thus adjusted in the desired range, depending on the application envisaged, by subjecting them to a further, so-called secondary, longitudinal stretching. This stretching is carried out when the hollow fibre is immersed in an 15 aqueous medium, for example water or a water/solvent mixture. The temperature of the stretching bath is generally from 50°C to 100 C and preferably from 80 C to 100°C. The secondary stretching ratio is generally from 1/1 to 10/1 and preferably from 1.5/1 to 6/1.
To provide the stretched fibres with a good dimensional stability on storage, it is necessary to subject them to a relaxation treatment. To do this, they are passed through one or more baths of water, the temperature of which is above the use and/or storage 25 temperature of the fibre. Generally, the temperature of the bath or baths is from 40°C to 100°C and preferably from i 14 Ο Ο 80 C to 100 C. The hollow fibre is generally guided between the inlet and outlet of the bath by rollers, the relative speeds of which are adjusted so that the fibre is constantly kept immersed and slack.
This relaxation bath also makes it possible to carry out an additional washing of the hollow fibre and to remove the traces of non-polymeric residues. The residence time of the hollow fibre in the relaxation and/or washing bath is generally less than one minute.
The new hollow fibres must be stored in the wet state in an aseptic medium, for example in aqueous formaldehyde solution. They can also be impregnated with a water-retention agent, such as ethylene glycol or, preferably, glycerol, by techniques which are in themselves 15 known.
The selectively permeable hollow fibres of the invention are of the symmetrical type and have a homogeneous microporous structure which is substantially uniform throughout their thickness. The average diameter 20 of the micropores is generally less than 100 A, this average diameter being determined by the method of D.M. GREEN et al., described in TRANS. AMER. SOC. ARTIP. INT. ORGANS, page 627 et seq., 1976. Moreover, the void factor is most frequently from U0% to 85% and preferably from 60% 25 to 80%. The hollow fibres are generally free of vacuoles (empty spaces included in the wall and having a largest is dimension of more than about 5 microns). They do not possess a skin or a dense layer on the surface, either on the inside or on the outside.
The external diameter of the hollow fibres is 5 generally from 50 to 2,000 microns and preferably from 100 to 500 microns. The wall thickness is generally from 3% to 30% of the external diameter, that is to say generally from 5 to 200 microns and preferably from 10 to 80 microns.
The walls, and especially the internal walls, of the new hollow fibres have a remarkably smooth, continuous and homogeneous surface condition on the microscopic scale, even at very high magnification.
The present invention makes it possible, 15 surprisingly, to obtain hollow fibres virtually devoid of roughnesses, either as pits or in relief, and in particular of roughnesses exceeding a height of about 0.3 micron relative to the average surface, as distinct from the hollow fibres obtained according to U.S. Patent 20 No. h,056,467.
Moreover, such roughnesses, if they exist, remain the exception; for example, the interior of each fibre of a haemodialyser as described in the Examples below possesses at most only one or two roughnesses of this 25 kind. Preferably, the internal surface of the hollow fibres of the invention possess non-uniformities of relief, 16 the height (or depth) of which does not exceed 0.1 micron. Moreover, such non-uniformities of relief do not generally have a sharp edge or an acute angle on the microscopic scale, but constitute microundulations, which 5 are frequently anisotropic in the plane of the surface of the hollow fibre and progressively joined together in a continuous manner.
If the average height of these undulations is designated by h and their average width by 1, it is 10 observed that the hollow fibres of the invention have an internal wall for which the ratio ^ is generally less than 25¾ and preferably less than 15%.
It is believed that the excellent condition of the internal surface of the hollow fibres of the 15 present invention makes a very substantial contribution towards reducing the risk of adhesion of platelets to the walls, the platelets having dimensions of the order of 2 microns. The formation of clots, possibly capable of subsequently causing thromboses, is thus avoided or 20 considerably retarded.
The following Examples illustrate the invention. Examples Nos. 6, 7 and 8 show a better haemocompatibility of the hollow fibres of the invention, which produce relatively much better results in experiments carried out 25 in vivo. 17 EXAMPLE 1 The following are introduced into a dissolver under a nitrogen atmosphere: - 210 g of an acrylonitrile/sodium methallylsulphonate 5 copolymer containing 3.2% by number of sulphonic comonomer, the specific viscosity of the copolymer being 0.95, - 312 g of Ν,Ν-dimethylformamide, and - 78 g of 2-butoxyethanol.
The mixture is stirred for 2 hours and heated to 145°C, and the stirring is continued for a further 2 hours. The stirring is stopped to prevent the entrainment of bubbles, and the composition obtained is introduced by means of a gear pump into a spinneret with an annular slit 15 of diameter 860/590 microns, provided with an axial orifice of diameter 370 microns for the introduction of air, the assembly being equipped with heating means O keeping the composition at a temperature of 128 C.
The hollow fibre formed travels vertically 20 downwards over a distance of 160 cm in the atmosphere, during which a solid gel is formed which is capable of winding around guiding and primary stretching rollers without suffering permanent deformation.
The hollow fibre is then subjected to a secondary 25 stretching with immersion in a bath of water at 98°C, and then successively to a first washing with water at ambient 18 temperature, to a stabilisation treatment by immersion in a bath of water at 95°C, and to a second washing with water at ambient temperature, after which it is stored in. the wet state on reels.
If the process according to the present invention and the process according to U.S. Patent No. 4,056,467 are carried out successively under conditions which are as similar as possible, in particular using identical spinnerets, the operating conditions and the 10 results obtained are as shown in Table I below: TABLE I ACCORDING TO ΓΗΕ INVENTION ACCORDING TO U.S. PATENT 4,056,467. Output of gear pump 1.75 cm2/minute 2 3.5 cm /minute 15 Air flow 6.2 cm /minute - Speed at spinneret outlet 5.8 m/minute - 20 Speed of take-up of gel or coagulated fibre 29 m/minute 9 m/minute Stretching ratio (secondary) aftei stabilisation 2.3 2.2 25 Thickness of fibres and external diameter/ internal diameter 22 μ (280/236) ji 74 (443/295) 30 Ultrafiltration capacity 35 -Flow of saline (9 g/litre gf NaCl) at 20 C under 0.5 bar 265 litres/day. m2 150 litres/day. m2 -Bovalbumin rejection factor 100% 100% 19 It is thus observed that the present invention makes it possible to obtain, with a much better productivity (29 m/minute compared with 9 m/minute starting from half the flow of solution), a thinner hollow fibre 5 having a higher ultrafiltration factor and also a 100% bovalbumin rejection factor.
EXAMPLE 2 3 hollow fibres are prepared in succession, namely a hollow fibre A according to the invention, 10 under the conditions of Example 1, a hollow fibre B according to the invention, under the conditions of Example 1 but with an additional secondary stretching similar to the previous one, and finally a hollow fibre C according to U.S. Patent No. 4,056,467.
For glycerinated fibres, the operating conditions and the results obtained are as shown in Table II below: 30 TABLE II FIBRE A FIBRE B FIBRE C Primary stretching ratio 2.6 2.6 - 1st secondary stretching ratio 3.8 1.9 4 5 2nd secondary stretching ratio - 2.4 - Stabilised overall stretching ratio 3.05 3.8 2.9 10 Thickness of the fibre external diameter/ internal diameter 32 u (298/234) 31 μ (313/251] 76 u (44(/288) 15 Flow of saline (9 g/0 litre of NaCl) at 40 C in litres/day./m2 under 0.5 bar 218 189 160 Mechanical characteristics : -Modulus of elasticity, E(kg/mm2) 49 60 34 20 -Elongation at break,% 38 30 58 -Tensile strength, T (kg/mm2) 3.4 4.5 1.45 Figure 1 shows the values of T and E as a function of the temperature, for hollow fibres A, B and 25 C immersed in water and non-glycerinated. First, a distinct superiority, from the point of view of the mechanical strength, of the fibres A and B according to the invention over the fibre C is observed. Secondly, it is observed that the additional stretching undergone 30 by fibre B very substantially improves its mechanical properties, but at the expense of a slight drop in the ultrafiltration rate. 21 EXAMPLE 3 - 1,050 g of the copolymer according to Example 1, - 1,560 g of Ν,Ν-dimethylformamide, and 390 g of 2-butoxyethanol: 5 are suitably mixed for 6 hours at a temperature of 50°C and the mixture is introduced into an extruder equipped with a feed screw of diameter 2.5 cm and length 50 cm.
The extruder feeds a proportioning pump which discharges into a spinneret having an annular orifice of 10 diameter 1,200/860 microns, with the introduction of axial air through an orifice of diameter 500 microns, O the assembly being thermostatically controlled at 125 C.
The speed of the hollow fibre after the primary stretching is 20 m/minute and the primary stretching ratio 15 is k. The secondary stretching ratio in water at 98°C is 3.8, which is brought down to 2.4 after stabilisation O in water at 98 C. This gives a hollow fibre having an internal diameter of 302 microns, with a thickness of 50 microns.
A haemodialyser is constructed which consists essentially of a bundle of 5,000 fibres having a useful 2 area of 0.86 m . The following are measured: . the vitamin B12 clearance: K = 60 ml.minute-^, and . the ultrafiltration gradient, that is to say: UF = 31 25 ml x hour-''' x mm Hg.
EXAMPLE 4 The same composition as in Example 3 is subjected to a primary stretching ratio of 4. The speed of the solution leaving the spinneret is 25 m/minute. The 5 secondary stretching ratio is 4, which is brought down to 2.8 after stabilisation in water at 98°C.
A haemodialyser is constructed which consists of a bundle of 6,000 hollow fibres having a useful area 2 of 1.14 m . The fibres have an internal diameter of 10 290 microns and a thickness of 50 microns. The following are measured: . the urea clearance: K = 168 ml x minute-·*·, . the B12 clearance: K = 79 ml x minute-^, and . the ultrafiltration gradient: UF = 44 ml x hour-^ x mm Hg. 15 These performance characteristics obtained in vitro compare favourably with those produced by the best haemodialysers currently available.
EXAMPLE 5 A hollow fibre according to the present invention 20 is prepared under the same conditions as those of Example No. 4, but the 2-butoxyethanol is replaced by the same amount of glycerol. Furthermore, a reference hollow fibre, with the same polymer composition, is prepared under the conditions of U.S. Patent No. 4,056,467.
Figure 2 shows a photograph, obtained on a scanning electron microscope (magnification 8,600 x), 23 of a sample of the internal wall of the hollow fibre prepared in this way, according to the invention.
Figure 3 shows a photograph, obtained under the same conditions and with the same magnification, of 5 a sample of the internal wall of the reference hollow fibre.
At this very high magnification, it is noted that the hollow fibre according to the invention has a continuous smooth surface virtually devoid of roughnesses, 10 whereas the reference hollow fibre has a rough surface showing discontinuities. The white line in the bottom right-hand corner of each photograph corresponds to a length of one micron.
EXAMPLE 6.
Two haemodialysers, A and B, are prepared.
Haemodialyser A comprises 5,000 hollow fibres with a useful length of 21 cm and extemal/internal diameters of 336/262 microns, obtained by extruding a composition similar to that of Example 3, in which the 20 2-butoxyethanol has been replaced by the same amount of glycerol, with a speed after primary stretching of 16 m/minute and a secondary stretching ratio of 4.7, which is brought down to 2.8 after stabilisation.
Haemodialyser B is used as a control. It is 25 similar to the previous haemodialyser and differs therefrom only in the hollow fibres, which have external/ 34 internal diameters of 450/300 microns and are prepared according to U.S. Patent No. 4,056,467.
A haemodialysis treatment is carried out for 3 hours on a heparin-treated dog weighing 20 kg, the two 5 haemodialysers, A and B, being arranged and fed simultaneously in parallel.
A blood flow of 200 ml/minute and an ultrafiltration rate of 10 ml/minute are maintained in each haemodialyser and the amounts of heparin are adjusted to 10 give a simultaneous and continuous operation of the two haemodialysers, while the haematocrit rises from 27% to 32%.
It is observed that, during the experiment, the pressure loss in the blood circuit across haemodialyser 15 A always remains less than 20 ram Hg, while for haemodialyser B, it rises very rapidly to 250 mm Hg and then remains above 180 mm Hg.
Moreover, after rinsing with 500 ml of physiological saline, haemodialyser A is clean, while the ends 20 of the hollow fibres of haemodialyser B remain covered with fibrin.
EXAMPLE 7 A haemodialyser C is prepared which comprises 6,000 hollow fibres with a useful length of 21 cm and 25 external/intemal diameters of 400/300 microns, obtained by extruding a composition similar to that used in the preparation of haemodialyser A of Example 6, but with a speed after primary stretching of 25 m/minute and a secondary stretching ratio of 4, which is brought down to 2.6 after stabilisation.
The reference haemodialyser D is a widely used apparatus; it is a C - DAK - 1.3 D model equipped with cellulose acetate hollow fibres having a useful area of 2 1.3 m , sold by the American Company CORDIS DOW CORPORATION.
A haemodialysis treatment is carried out on a dog weighing 20 kg, under conditions similar to those of Example 6, haemodialysers C and D being arranged in parallel.
It is observed that, during the 3 hour treatment, 15 the pressure loss in the blood circuit across haemodialyser C remains between 20 and 30 mm Hg, while for control haemodialyser D, it rises rapidly to 60 mm Hg and then stays between 55 and 60 mm Hg.
After rinsing of the haemodialysers, the 20 following residual volumes of blood are moreover observed; - 14 ml for haemodialyser C - 23 ml for haemodialyser D.
It will be noted that these figures are high because they refer to an experiment on a dog with a 25 relatively high haematocrit increasing from 29% to 39%. 26 EXAMPLE 8 A haemodialyser E is prepared which comprises 6,000 hollow fibres with a useful length of 21 cm and external/intemal diameters of 390/290 microns, obtained 5 in a manner similar to the preceding example.
The control haemodialyser F is a type B2M FILTRYZER apparatus equipped with polymethyl methacrylate hollow fibres, sold by the Japanese Company TORAY INDUSTRIES INC.
The process is carried out under conditions similar to those of Example 7, and it is observed that the pressure loss in the blood circuit across haemo-dialyer E remains between 20 and 27 mm Hg, while for control haemodialyser F, it rises gradually to 50 mm Hg 15 and stays above 45 mm Hg. The residual volumes of blood after rinsing are respectively 1.9 and 3.6 ml for haemodialyser s E and F.
Claims (14)
1. 27
2. 1. Semi-permeable hollow fibre of the symmetrical type consisting of a copolymer of acrylonitrile and an olefinically unsaturated comonomer carrying sulphonic acid groups which may be salified, and having a homogeneous microporous structure of a gel obtained essentially by lowering the temperature of a solution of the said copolymer by means of air or of an inert fluid which is immiscible with the constituents of the said solution during gelling, followed by washing.
3. 2. Hollow fibre according to claim 1, having an internal surface which is smooth on the microscopic scale, and virtually devoid of roughnesses having a height of more than 0.3 micron.
4. 3. Hollow fibre according to claim 1 or 2, having an interal surface which is continuous and possesses, on the microscopic scale, only microundulations having a gradient of less than 25%.
5. 4. Hollow fibre according to any one of claims 1 to 3 having a void factor of 40 to 85% and an average pore diameter less than 100 8.
6. 5. Hollow fibre according to any one of claims 1 to 4 having an external diameter of 100 to 500 microns, and a wall thickness of 10 to 80 microns, the wall thickness being 3 to 30% of the external diameter.
7. 6. Hollow fibre according to any one of claims 38 1 to 5 made of a copolymer of acrylonitrile and sodium methallylsulphonate. 7. process for the preparation of hollow fibres as claimed in any one of claims 1 to 6 which comprises: 5 (a) preparing a composition from a copolymer or acrylonitrile and an olefinically unsaturated comonomer carrying sulphonic acid groups which may be salified, a polar organic solvent, and an adjuvant, which is a poor solvent or is not a solvent for the copolymer, is miscible 10 with the solvent or mixture of solvents and preferably also with water and which does not contain any component capable of reacting with the components of the said composition which would result in the formation of an irreversible gel before washing, 15 (b) bringing the composition into the state of a homogeneous solution which can be spun at a temperature above its gel temperature, (c) spinning the said solution through a spinneret, to form a hollow fibre and cooling the hollow fibre thus 20 formed until it gels, and (d) washing the gelled hollow fibres to remove the non-polymeric residues therefrom.
8. Process according to claim 7, in which the spun hollow fibre is cooled until it gels by bringing the 25 internal and external surfaces of the fibre into contact with the atmosphere.
9. Process according to claim 7 or 8, in which 39 as soon as it leaves the spinneret, the hollow fibre is subjected to a primary longitudinal stretching in a ratio of 1/1 to 20/2.
10. Process according to any one of claims 7 to 9, in which the hollow fibre after washing is subjected to at least one secondary longitudinal stretching in a ratio of 1/1 to 10/1 while it is immersed in an aqueous bath at a temperature of 50 to 100°C.
11. Process according to claim 9 or 10, in which after stretching, the hollow fibre is subjected to a relaxation treatment by immersion in at least one bath of water at a temperature of 40°C to 100°C.
12. Haemodialyser, haemofliter, ultrafilter or plasmapheresis apparatus at least partially equipped with hollow fibres according to any one of claims 1 to 6 or with hollow fibres obtained by a process according to any of claims 7 to 11.
13. A hollow fibre as claimed in claim 1 substantially as described in any one of Examples 1 to 4.
14. A haemodialyser according to claim 12 substantially as hereinbefore described. F. R. KELLY & CO., AGENTS FOR THE APPLICANTS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8211788A FR2529464B1 (en) | 1982-07-01 | 1982-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE831535L IE831535L (en) | 1984-01-01 |
IE55578B1 true IE55578B1 (en) | 1990-11-07 |
Family
ID=9275698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE1535/83A IE55578B1 (en) | 1982-07-01 | 1983-06-30 | Hollow fibre useful in blood treating processes |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0100285B2 (en) |
JP (1) | JPS5967964A (en) |
DE (1) | DE3365863D1 (en) |
FR (1) | FR2529464B1 (en) |
IE (1) | IE55578B1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8501111L (en) * | 1985-03-07 | 1986-03-03 | Gambro Dialysatoren | SET TO MAKE A SEMIPERMEABLE HALFIBER |
US4970034A (en) * | 1988-09-23 | 1990-11-13 | W. R. Grace & Co.-Conn. | Process for preparing isotropic microporous polysulfone membranes |
FR2663546B1 (en) * | 1990-06-25 | 1995-05-12 | Hospal Ind | HEMOCOMPATIBLE COMPOSITE MATERIAL. |
US5096585A (en) * | 1991-01-28 | 1992-03-17 | W. R. Grace & Co.-Conn. | Process for preparing protein non-adsorptive microporous polysulfone membranes |
US5151227A (en) * | 1991-03-18 | 1992-09-29 | W. R. Grace & Co.-Conn. | Process for continuous spinning of hollow-fiber membranes using a solvent mixture as a precipitation medium |
FR2696658B1 (en) * | 1992-10-14 | 1994-11-18 | Hospal Ind | Method and device for encapsulating a substance, as well as the capsule obtained. |
GB9311988D0 (en) * | 1993-06-10 | 1993-07-28 | Pall Corp | Device and method for separating plasma from a blood product |
FR2721217B1 (en) * | 1994-06-20 | 1996-08-02 | Hospal Ind | Multifunction device for the treatment of blood. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1586563A (en) * | 1968-10-29 | 1970-02-20 | ||
FR2196184B1 (en) * | 1972-08-16 | 1976-11-19 | Toray Industries | |
FR2199014B1 (en) * | 1972-09-12 | 1975-03-14 | Rhone Poulenc Ind | |
FR2421656A1 (en) * | 1978-04-03 | 1979-11-02 | Japan Exlan Co Ltd | PROCESS FOR THE PRODUCTION OF ACRYLONITRILIC SEPARATION MEMBRANES |
-
1982
- 1982-07-01 FR FR8211788A patent/FR2529464B1/fr not_active Expired
-
1983
- 1983-06-28 DE DE8383420105T patent/DE3365863D1/en not_active Expired
- 1983-06-28 EP EP83420105A patent/EP0100285B2/en not_active Expired
- 1983-06-30 JP JP58117208A patent/JPS5967964A/en active Granted
- 1983-06-30 IE IE1535/83A patent/IE55578B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
FR2529464B1 (en) | 1985-01-18 |
EP0100285B2 (en) | 1989-03-22 |
JPS5967964A (en) | 1984-04-17 |
DE3365863D1 (en) | 1986-10-09 |
JPH0371144B2 (en) | 1991-11-12 |
FR2529464A1 (en) | 1984-01-06 |
EP0100285A1 (en) | 1984-02-08 |
IE831535L (en) | 1984-01-01 |
EP0100285B1 (en) | 1986-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4749619A (en) | Hollow fibre useful in blood treating processes | |
JP2916446B2 (en) | Method for producing asymmetric microporous hollow fiber | |
US4612119A (en) | Hollow fiber filter medium and process for preparing the same | |
EP0504686B1 (en) | Process for continuous spinning of hollow-fiber membranes using a solvent mixture as a precipitation medium | |
EP0193725B1 (en) | Process for spinning hollow fiber membranes | |
US4439322A (en) | Polymethyl methacrylate membrane | |
US4780205A (en) | Permselective hollow fiber membrane, process for the preparation thereof, method and apparatus for plasma components separation | |
JPH02151636A (en) | Preparation of isotropic microporous polysulfone film | |
US3896061A (en) | Semi-permeable membranes, their preparation and their use | |
EP0747113A2 (en) | Polyvinyl alcohol-based hollow fiber membrane and process for producing the same | |
JP2006507931A (en) | Membrane and its use | |
JPS5865009A (en) | Production of asymmetric polyamide hollow yarn membrane | |
GB2050935A (en) | Hollow fibre membranes of ethylene-vinylalcohol copolymer | |
EP0012630B1 (en) | Process for producing a cellulose acetate-type permselective membrane, permselective membrane thus produced, and use of such membrane in artificial kidney | |
IE55578B1 (en) | Hollow fibre useful in blood treating processes | |
US4181606A (en) | Lactam terpolymer membranes | |
GB2047161A (en) | Hollow fiber form polycarbonate membrane for use in dialysis and process for producing same | |
CN112044289B (en) | Dialysis membrane for high-efficiency hemodialysis instrument and preparation method | |
JPH0611320B2 (en) | Hollow fiber membrane for hemodialysis | |
JPS6336805B2 (en) | ||
US4274965A (en) | Lactam terpolymer membranes | |
JP3872173B2 (en) | POLYHYDROXY ETHER RESIN AND METHOD FOR SYNTHESIZING THE SAME, POLYHYDROXY ETHER MEMBRANE AND METHOD FOR PRODUCING THE SAME | |
CN114749032B (en) | PMP hollow fiber membrane and preparation method and application thereof | |
JPS6329562B2 (en) | ||
JPH0670155B2 (en) | Manufacturing method of polytetrafluoroethylene resin porous membrane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed |